On a high level, MighTy is trying to do using DNA what Moderna is trying to do using RNA - manufacture mAbs within the patients, which would be a big threat to the expensive checkpoint inhibitors industry. As you may know, Moderna is privately valued at $3B (used to be $5B).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.